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BACKGROUND: The composite histological endpoint comprising nonalcoholic
steatohepatitis (NASH) and NAFLD activity score ≥4 and advanced fibrosis (F ≥ 2)
("fibrotic NASH") is becoming an important diagnostic target in NAFLD: it is
currently used to select patients for inclusion in phase III therapeutic trials and will
ultimately be used to indicate treatment in clinical practice once the new drugs are
approved.
AIM: To develop a new blood test specifically dedicated for this new diagnostic
target of interest.
METHODS: Eight Hundred and forty-six biopsy-proven NAFLD patients from three
centres (Angers, Nice, Antwerp) were randomised into derivation and validation
sets.
RESULTS: The blood fibrosis tests BARD, NFS and FIB4 had poor accuracy for
fibrotic NASH with respective AUROC: 0.566 ± 0.023, 0.654 ± 0.023,
0.732 ± 0.021. In the derivation set, fibrotic NASH was independently predicted by
AST, HOMA and CK18; all three were combined in the new blood test MACK-3
(hoMa, Ast, CK18) for which 90% sensitivity and 95% specificity cut-offs were
calculated. In the validation set, MACK-3 had a significantly higher AUROC
(0.847 ± 0.030, P ≤ 0.002) than blood fibrosis tests. Using liver biopsy in the grey
zone between the two cut-offs (36.0% of the patients), MACK-3 provided excellent
accuracy for the diagnosis of fibrotic NASH with 93.3% well-classified patients,
sensitivity: 90.0%, specificity: 94.2%, positive predictive value: 81.8% and negative
predictive value: 97.0%.
CONCLUSION: The new blood test MACK-3 accurately diagnoses fibrotic NASH.
This new test will facilitate patient screening and inclusion in NAFLD therapeutic
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